fbpx Skip to main content

THURSDAY, Feb. 25, 2021 (HealthDay News) — A machine learning-based model has been developed and validated for predicting malignancy in multiple pulmonary nodules (MPNs), according to a study published online Feb. 24 in Clinical Cancer Research.

Kezhong Chen, M.D., from the Peking University People’s Hospital in Beijing, and colleagues developed and validated a machine learning-based model to estimate the malignant probability of MPNs. Clinicoradiologic variables of 1,739 nodules from 520 patients with MPNs were used to predict malignancy with a boosted ensemble algorithm. Tenfold cross-validation was used to train the model (PKU-M model), which was then validated and compared with solitary pulmonary nodule models, clinicians, and a computer-aided diagnosis (CADx) system.

The researchers found that in the development cohort, the PKU-M model showed excellent discrimination (area under the curve [AUC], 0.909) and calibration (Brier score, 0.122). In external validation with 583 nodules, the AUC of the PKU-M model was 0.890, which was higher than those of the Brock model, PKU model, Mayo model, and VA model (AUCs, 0.806, 0.780, 0.739, and 0.682, respectively). The AUC of the PKU-M model (0.871) was higher than that of three thoracic surgeons (0.790, 0.741, and 0.727), a radiologist (0.748), and the CADx system (0.757) in prospective comparisons including 200 nodules. The model outperformed clinicians with increases of 14.3 and 7.8 percent in sensitivity and specificity, respectively.

“This first cancer prediction model specifically for MPNs demonstrated solid performance as a convenient reference to help decision-making,” the authors write.

One author disclosed ties to Johnson & Johnson.

Abstract/Full Text

You May Also Like::  Many Adults Do Not See Link Between Racism, Poorer Health

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.


New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More